EDITORIAL Nov 2020 – Solidarity

Editorial Logo
Written by Alan V. Schmukler

EDITORIAL Nov 2020 – Solidarity – Alan V. Schmukler

The Solidarity trial is an international clinical trial started by the World Health Organization (WHO) to determine an effective treatment for COVID-19. One of the largest such studies, it enrolled 12,000 patients at 500 hospital sites in over 30 countries.

The trial evaluated possible COVID-19 drugs for their effects on mortality, need for assisted ventilation and duration of hospital stay.

On October 15, 2020 the WHO Solidarity trial found that the drug Remdesivir :

had little or no effect on overall mortality, initiation of ventilation and duration of hospital stay in hospitalized patients.”

And yet, a week later on October 22, the U.S. Food and Drug Administration (FDA) approved Remdesivir for use against COVID. They granted Remdesivir an emergency use authorization (EUA) to include all hospitalized COVID-19 patients. It was the first drug to receive that status.

FDA Commissioner Stephen M. Hahn, M.D.  stated, “Today’s approval is supported by data from multiple clinical trials that the agency has rigorously assessed.”

That decision would help profits of Gilead Sciences Inc. which markets Remdesivir.  Gilead expects sales of Remdesivir to increase revenue by as much as $2.8 billion in 2020.

It was reported in the journal SCIENCE (3) that the FDA never consulted the independent experts at the Antimicrobial Drugs Advisory Committee (AMDAC), which has massive resources for reviewing research. That consultation would have been the reasonable thing to do with such an important decision.

Dr. Eric Topol, editor-in-chief of Medscape objected to FDA’s approval of Remdesivir.  He published a stinging rebuke to FDA Commissioner Stephen Hahn on Medscape under the headline “Tell the Truth or Resign.” Referring to the Remdesivir approval and the FDA’s previous authorizations for hydroxychloroquine and convalescent plasma (also proved ineffective) he stated:

“These repeated breaches demonstrate your willingness to ignore the lack of scientific evidence, and to be complicit with the Trump Administration’s politicization of America’s healthcare institutions.”

What has all this to do with homeopathy?  It is the FDA’s new “draft guidance” for homeopathy, which if finalized, would ban virtually all homeopathic remedies in the U.S.  Opposing this is American’s for Homeopathy Choice, and other organizations, which have asked everyone to post comments on the FDA website opposing the new draft guidance.  https://homeopathychoice.org/fdacomment/ .

We must not let one corrupt regulatory agency rob Americans of one of the most effective, safe and affordable healing methods for COVID and other ailments. If the FDA succeeds, it will invite other countries to also impose draconian measures suppressing homeopathy.

In the U.S., add your comments to support homeopathy at:

If you are from outside the U.S. comment here:


Let us stand together in solidarity



Editorial – Solidarity  –  Alan V. Schmukler

–– Letters to the Editor – Feedback from Oct 2020



Dr. Robert Melo is interviewed by Paola Brown. Dr. Melo is president of OHM Pharma, manufacturer of homeopathic medicines and member of the HPCUS and the Liga. Paola Brown is President of Americans for Homeopathy Choice.



–– Online Homeopathy Course by George Vithoulkas

–– 50% Discount on Homeopathy Foundation Course

–– Buy Dr. Bhatia’s Lectures on Organon of Medicine – the International bestseller!



–– Aurum Metallicum: The Bittersweet Anguish of Theosis – Molly Caliger

––Homeopathy in Israel During the First Half Year of the COVID-19 Pandemic  – Rakhel Shabi

–– The Prostrating Prostate – Ajit Kulkarni

––  Homeopathy: Safe Effective Natural Medicine – Hospitalized Patients Rescued –  Judyth Reichenberg-Ullmann

–– Homeopathy in the Systems View of Science – László V. Szabó 

–– The Soul of Remedies  – Bryonia Alba – Rajan sankaran

–– Ulcerative Colitis and Its Homeopathic Approach – Jagdish Thebar

–– Tidbits 74: Blatta–Under-used Remedy in Asthma (COVID Too?)” – Elaine Lewis

–– Tips & Secrets – November 2020 – Alan V. Schmukler



–– Clinical Experiences in the Pandemic of Covid 19 (Case Series Vol. 3 ) Gyandas G. Wadhwani

–– COVID-19 in a Woman of 65 -Martine Mercy

–– Idiopathic Pulmonary Fibrosis – Ardeshir T. Jagose

–– Ozonum – “I Can’t Breathe” – Ozonum in COVID-19 – Petr Simeon Gajdos

––  Post-COVID-19 Syndrome in a woman of 40 – Grace DaSilva-Hill

–– Chronic Calcific Pancreatitis with Neoplasm, Diabetes, Enlarged Prostate and Mental Trauma – Kavita Chandak

–– Hypothyroidism in a Woman of 43 – Vibha Mevada

––  Endometriosis and Infertility – Treated with Homeopathic Detox Therapy – Ton Jansen

–– Adenomyosis in a Woman of 47 – Rashmi Rani

–– Polycystic Ovarian Syndrome in a Woman of 29 – Chanda Shah

–– Burning During / After Micturation – Minal Dhas



–– Aqueous Dilutions in Centesimal Scale Form Solute-Specific Structures – Prof. C. R. Mahata



–– Pregnancy and Childbirth with Homeopathy by Guðný Ósk Diðriksdóttir -Reviewed by Rochelle Marsden



–– Ask the Holistic Vet – November 2020 – Deva Khalsa



–– The Plant Doctor – November 2020 – Radko Tichavsky



–– Grotesque!  – Alan V. Schmukler



––  Homeopathy Crossword November 2020



–– Revisiting: Tearing My Hair Out! – Elaine Lewis

–– QUIZ –Spider Bite! –  Elaine Lewis

About the author

Alan V. Schmukler

Alan V. Schmukler is a homeopath, Chief Editor of Homeopathy for Everyone and author of ”Homeopathy An A to Z Home Handbook”, (also in French, German, Greek, Polish and Portuguese). He is Hpathy’s resident cartoonist and also produces Hpathy’s Tips & Secrets column and homeopathy Crossword puzzles each month. Alan is a recipient of the National Center for Homeopathy Martha Oelman Community Service Award. Visit Alan at his website: Here.

Leave a Comment